MTN-038 was a Phase I study of a 90-day vaginal ring containing tenofovir that was developed to protect women against both HIV and herpes simplex virus type 2 (HSV-2). The study assessed the safety of the ring and drug levels in tissue among 49 women at three U.S. trial sites. Results, which were reported at the 2022 Conference on Retroviruses and Opportunistic Infections, found the ring was well-tolerated and acceptable but that in a subset of participants there was more rapid release of tenofovir from the ring.
MTN researchers begin safety study of a 90-day vaginal ring containing tenofovir
MTN-038 Study Page